<DOC>
	<DOCNO>NCT00232661</DOCNO>
	<brief_summary>The purpose study compare tamoxifen , versus newer treatment , ARIMIDEX , already know well tolerate . The main objective research study see whether use drug shrink tumour surgery see shrinkage tumour affect extent surgery require .</brief_summary>
	<brief_title>PROACT - Pre-Operative Arimidex Compared To Tamoxifen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Operable potentially operable breast cancer Invasive breast cancer proven hormonesensitive ( ER+/PR+ ) Patients might benefit endocrine treatment prior surgery Postmenopausal Signed write informed consent Inoperable breast cancer Patient unwilling undergo surgery Any reason patient may able conform study requirement Any previous treatment breast cancer Previous Tamoxifen use part breast cancer prevention trial Not willing stop taking drug affect sexhormones HRT Previous history breast cancer Previous history invasive malignancy within last 10 year Any severe disease may prevent surgery , place patient risk , influence study result Treatment experimental drug within last 3 month Risk transmit HIV , Hepatitis B C</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>